

Minoli Perera Pharm.D. Ph.D.

Department of Pharmacology
Center for Pharmacogenomics
303 E. Chicago Ave, Ward 9-188
Chicago, IL 60611
Office: (312) 503-6188
minoli.perera@northwestern.edu

ACADEMIC APPOINTMENTS

August 2006 – July 2009	Instructor , The University of Chicago, Section of Genetic Medicine and Committee on Clinical Pharmacology and Pharmacogenomics, Department of Medicine.
July 2009 – December 2015	Assistant Professor , The University of Chicago, Section of Genetic Medicine and Committee on Clinical Pharmacology and Therapeutics, Department of Medicine.
January 2016 – June 2016	Associate Professor , The University of Chicago, Section of Genetic Medicine and Committee on Clinical Pharmacology and Therapeutics, Department of Medicine.
July 2016 – Present	Associate Professor , Northwestern University, Department of Pharmacology, Center for Pharmacogenomics.

Pb.D.-Granting Committee, Program, Institute, and Center Appointments

2006	Committee on Clinical Pharmacology and Pharmacogenomics
2010	Center for Personalized Therapeutics
2013	Committee on Molecular Medicine
2014	Genetic, Genomics and Systems Biology
2014	Cardiovascular Sciences Training Grant
2016	Driskill Graduate Program

ACADEMIC TRAINING

November 1995- August 1997	Student Assistant , University of Tennessee, Department of Anatomy and Neurology, Mentor: Dr. Anton Reiner
May 1995-August 1995	Student Assistant , University of Tennessee, Department of Pharmaceutical Sciences, Mentor: Dr. Atul Shukla
August 1997– December 2000	Graduate Student , University of Tennessee, Department of Pharmaceutical Sciences
January 2000–December 2003	Graduate Student , The Ohio State University, Division of Pharmaceutics.
February 2004- February 2006	Fellow , The University of Chicago, Committee on Clinical Pharmacology and Pharmacogenomics, Mentor; Dr. Anna Di Rienzo

EDUCATION

1989 – 1993	Diploma , Bishop Byrne High School, Memphis TN,
1993 – 1997	B.S., Biology , Christian Brothers University, Memphis TN Summa Cum Laude, May 1997
1997 – 2001	Pharm.D. , University of Tennessee; College of Pharmacy, Memphis TN Pharm.D/ Ph.D. Dual Degree Program
2001 – 2003	Ph.D. , The Ohio State University, Columbus OH Division of Pharmaceutics Dissertation Title “Pharmacology, Pharmacokinetics and Metabolism of Selective Androgen Receptor Modulators.”

CLINICAL EXPERIENCE

May 1998 – December 1998	Pharmacy Intern , Veteran’s Administration Medical Center, Memphis TN Inpatient Pharmacy
October 2002- December 2003	Pharmacist , Big Bear Pharmacy, Columbus, Ohio
November 2008 – Present	Clinical Pharmacology Consult Service Director , The University of Chicago, Clinical Pharmacology Consult Service Committee on Clinical Pharmacology and Pharmacogenomics, Department of Medicine.

- Overseeing the consults made by the Clinical Pharmacology fellows.
- Utilizing consults as a teaching tool for within the fellowship program
- Implementation/integration of consults into EPIC
- Attending on service 3-6 months/year
- Integration into pharmacy residency program

CERTIFICATES AND LICENSES

Certified in Anticoagulation Management, 2008
 Registered Pharmacist, State of Ohio, June 2002 to 2011, License #03-2-24794
 Registered Pharmacist, State of Illinois, June 2006 to present, License # 051291144
 CPR certified
 Certified to administer immunizations

HONORS AND AWARDS

1993	Summa Cum Laude, Christian Brothers University
1997	Pharm.D/ Ph.D. dual degree program, University of Tennessee
1999	Merck Undergraduate Research Scholar, American Association of Colleges of Pharmacy
2000	Charles and Henry Shapard Scholarship, University of Tennessee
2000	Feurt Scholar, University of Tennessee
2001	Merck Award for Scholastic Achievement, University of Tennessee
2002	AFPE Fellowship, The Ohio State University
2011	Faculty of 1000, Manuscript selected as high impact paper
2013	Invited Junior Faculty, Workshop on Pharmacodynamics of Anticancer Agents
2013	Department of Medicine Diversity Award
2015	Invited, AAMC Early Career Women Faculty Professional Development Seminar
2016	Leon Goldberg Early Investigator Award from ASCPT.

PROFESSIONAL ORGANIZATIONS

American Association of Pharmaceutical Scientists
 2002 – 2006 - Member

American Society of Clinical Pharmacology and Therapeutics
 2004 – Present - Member
 2004 – Present - Molecular Pharmacology and Pharmacogenomics Section Member
 2012 – Present - Organ Specific Diseases Section Member
 2014 Scientific Program Committee

American College of Clinical Pharmacy
 2007 – 2013 - Associate Member, February

International Warfarin Pharmacogenomics Consortium
 2009 – Present - Member

American Heart Association
 2009 – 2013 - Member

Central Society of Clinical Research
 2010 – Present - Member

Pharmacogenetics Research Network
 2011 – Present - Affiliate Member

Clinical Pharmacogenomics Implementation Consortium (CPIC)
 2013 – present - Warfarin Pharmacogenomics CPIC Committee

COMMITTEES AND SERVICE

2004	Institutional Review Board, University of Chicago (Associate Member)
2005	Pharmaceutical and Therapeutics Committee, University of Chicago (Associate Member)

2009 - Present BSD Women's Committee, University of Chicago (Member)
2011 – Present Clinical Pharmacology and Pharmacogenomics Recruitment Committee (Member)
2010 – Present Pre-clinical Curriculum Review Committee, Pritzker School of Medicine (Member)
2015 – Present BSD TA Committee (GGSB Representative)

REVIEWER AND EDITORIAL SERVICE

Pharmacotherapy, Manuscript Reviewer
Pharmacogenetics and Genomics, Manuscript Reviewer
Clinical Pharmacology and Therapeutics, Manuscript reviewer
American College of Clinical Pharmacy, Expert Book Chapter reviewer
PLoS One, Manuscript Reviewer
Frontiers in Pharmacogenomics, Manuscript Reviewer and Review Editorial Board Member
Annals of Internal Medicine, Manuscript Reviewer.
JAMA, Manuscript Reviewer.
NIH Study Section Reviewer, Early Career Reviewer (ECR) program, XNDA(2014 – present)

TEACHING EXPERIENCE

2002 **Lecturer**, PHAR 622, Drug Delivery II, 3 credit hours, Division of Pharmaceutics, College of Pharmacy, The Ohio State University (5 hours, 15 students)
2005- 2007 **Lecturer**, MED 30777, Introduction to Pharmacology, 3 credit hours, Department of Medicine, taught 1 lecture on autonomic Pharmacology
2005 **Teaching Assistant**, MED 777, Advanced Clinical Pharmacology and Therapeutics, Department of Medicine, Conducted case studies review of topics in pharmacology.
2008 **Course Director**, MOLM 57000, The Good, the Bad and the Inflamed: Genomics of Pulmonary Disease. Course targeting Pulmonary clinical and research fellows, as a part of the K12 program in the Department of Medicine covering topics in both pulmonary medicine and pulmonary genomics. (16 hours, 25 students)
2010 - Present **Lecturer**, CCTS 4001/CABI 47500, Pharmacogenomics, Department of Medicine, Taught 3 classes. (3 hours, 100 units, 20 students)
2010 **Course Co-Director**, MEDC-30777, Pharmacology, Pritzker School of Medicine. Pharmacology for second year medical students. (35 hours, 86 students)
2010 – Present **Lecturer**, Women in Science Summer Intensive, Pritzker School of Medicine. Professional development for women University of Chicago medical students. (1 hour, 50 units, 20 students)
2009 – Present **Course Director**, CCTS 40003/CABI 40400/MPMM 40400, Genetic Basis of Personalized Medicine. Department of Medicine (16 hours, 50 units, 25 students)
2011– Present **Course Director**, MEDC-30777, Pharmacology, Pritzker School of Medicine. Pharmacology for second year medical students. (35 hours, 88 students)
2016 **Lecturer**, CCTS 40400/20200, Health Disparities in Breast Cancer, Taught 1 classes. (1 hours, 100 units, 5 students)

RESEARCH TRAINEES

Post Doctoral Fellows

October 2011 – present **Wenddy Hernandez**, Cardiovascular Research Fellow
Abstracts Presented by Trainee
Hernandez W, Gamazon ER, Perry K, Aquino-Michaels K, Patel S, O'Brien T, Harralson A, Nicolae D, Cavallari LH, **Perera MA**. A Novel Pharmacogenomic Dosing Algorithm for African Americans Taking Warfarin: Able to Predict Where IWPC'S Algorithms Cannot. American Society of Clinical Pharmacology and Therapeutics, Indianapolis, IN 2013. *Presidential Trainee Award winner*
Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AF, Kittles RK, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae D, Cavallari LH, **Perera MA**. *VKORC1* and *CALU* eQTLs and susceptibility to venous thromboembolism among African Americans. American Society of Clinical Pharmacology and Therapeutics, Atlanta GA April 2014. *Presidential Trainee Award winner, Selected for oral presentation*

Hernandez W, Gamazon ER, Konkashbaev A, Kittles RA, Cavallari LH, **Perera MA**. Genome-wide association study identifies novel susceptibility loci for venous thromboembolism in African Americans. American Society of Human Genetics (ASHG) Meeting, San Diego, CA, 2014

Hernandez W, Gamazon ER, Konkashbaev A, Kittles RA, Cavallari LH, **Perera MA** Genome-wide Association Study Identifies Novel Susceptibility Loci for Venous Thromboembolism in African Americans. American Society of Clinical Pharmacology and Therapeutics (ASCPT), New Orleans, LA, 2015.

FUNDING

Source: NIH, National Heart Lung and Blood Institute, 1 F32 HL123311-01A1,
Title: Discovery of genomic copy number variants and expression quantitative trait loci that affect warfarin dose response in African Americans
Time Period: April 2015 – March 2017
Amount: \$165,000
Dr. Perera - Primary Mentor

April 2015 – Present

Tanima De, Postdoctoral Scholar

Abstracts Presented by Trainee

T. De, N. Nwanze, W. Hernandez, E. Smithberger, M. Tuck, T. O'Brien, R. Kittles, J. Duarte, S. Bourgeois, L. Cavallari, **M. Perera**. Genome-wide Association to identify the genetic determinants of warfarin induced hemorrhagic complication in African Americans. American Society of Clinical Pharmacology and Therapeutics (ASCPT), San Diego, 2016. *Presidential Trainee Award winner, Selected for poster walk*

Thesis Committee

June 2014 – Present

Samantha Thomas, MSTP student.
Primary Advisor: Yoav Gilad

Post Baccalaureate students

February 2011

Lucia Cortejoso, Foreign Pharm.D Resident, currently working as a Clinical Pharmacist at Hospital General Universitario Gregorio.

January 2014 – March 2015

Nneka Nwanze, Post Baccalaureate Student, initiated investigation genetic studies of bleeding risk in warfarin

Abstracts Presented by Trainee

Nwanze N, Hernandez W, Tuck M, O'Brien T, Kittles R, Duarte J, Bourgeois S, Cavallari LH, **Perera MA**. Genome-wide Association Study to Identify Susceptibility Loci Associated with Hemorrhagic Complications Among African American Patients on Stable Warfarin Dose. American Society of Clinical Pharmacology and Therapeutics (ASCPT), New Orleans, LA, 2015.

Undergraduate Students

May 2008 – August 2008

Megan Flynn, undergraduate summer student, currently a medical student at Georgetown University.

Abstracts Presented by Trainee

Perera MA, Cavallari LH, Patel S, Ramikie T, Flynn M, Cox, NJ. "A Pharmacogenetic study of novel SNPs in *VKORC1* and *CYP2C9* in African American cohorts." American Society of Human Genetics, Honolulu, HI 2009

May 2009 – August 2009

Stephanie Poindexter, undergraduate summer, currently an intern at the Pacific Primate Sanctuary and PhD candidate.

- January 2010 – July 2011 **Keston Aquino-Michaels**, Graduate Research Technician, currently a Graduate student, University of Chicago.
Abstracts Presented by Trainee
Cavallari LH, **Perera MA**, Wadelius M, Deloukas, Taube G, Patel SR, Aquino-Michaels K, Marlos A.G. Viana, Shapiro NL, Nutescu EA. "Association of the gamma-glutamyl carboxylase (CAA)16/17 repeat polymorphism with higher warfarin dose requirements African Americans". American College of Clinical Pharmacy Annual meeting, Pittsburg, PA 2011
- May 2011 – August 2011 **Riean Knight**, Undergraduate summer student, assisted in genotyping
- May 2011 – August 2011 **Alexander Flowers**, Pharm.D. student volunteer, assisted in analysis.
- September 2013 – present **Sara Kwan**, University of Chicago undergraduate Student, assisted in patient recruitment
- Summer 2013 and 2014 **Shavoria Grady**, Minority high school student, basic lab protocol and genotyping techniques.
- August 2014 – August 2015 **Mary Young**, 4th year medical student, Analysis on cost effectiveness data related to implementation of pharmacogenomics into the clinic.
- May 2015 – Present **Minnie Horvath**, University of Chicago undergraduate Student, assisted in cell based model development
- June 2015 – August 2015 **Ijezie Ikwuezunma**, Johnson Scholar at Washington and Lee University undergraduate summer student, genetic association of ROCK pathway genes with thrombosis in African Americans.

PEER - REVIEWED MANUSCRIPTS

1. Reiner A, **Perera MA**, Paullus R, Medina L. Immunohistochemical localization of DARPP32 in striatal projection neurons and striatal interneurons in pigeons. *J Chem. Neuroana.t* 16 (1998) 17-33.
2. He Y, Yin D, **Perera MA**, Kirkovsky L, Stourman N, Dalton JT and Miller DD. Novel Nonsteroidal Ligands with High Affinity and Potent Functional Activity for the Human Androgen Receptor. *European Journal of Medicinal Chemistry* 37: 619-637, 2002.
3. Yin D, He Y, **Perera MA**, Hong SS, Marhefka C, Stourman N, Kirkovsky L, Miller DD, and Dalton JT. Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor. *Molecular Pharmacology* 63: 211-223, 2003.
4. **Perera MA**, Wu D, Chan KK, Miller DD, and Dalton JT. In Vivo Metabolism and Final Disposition of a Novel Nonsteroidal Androgen in Rats and Dogs. *Drug Metabolism and Disposition* 34(10):1713-1721, 2006.
5. **Perera MA**, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. *The Pharmacogenomics Journal*, 2009 Feb;9(1):49-60 PMID: PMC2754748
6. Lodolce JP, Kolodziej LE, Rhee L, Kariuki SN, Franek BS, McGreal NM, Logsdon MF, Bartulis SJ, **Perera MA**, Ellis NA, Adams EJ, Hanauer SB, Jolly M, Niewold TB, Boone DL. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. *J Immunol.* 2010 Jun 15;184(12):7001-9.
7. **Perera MA**, Gamazon E, Cavallari LH, Patel SR, Flynn M, Poindexter S, Kittles RA, Nicolae DA, Cox NJ. The Missing Association: Sequencing-based discovery of novel SNPs in *VKORC1* and *CYP2C9* that affect warfarin dose in African Americans. *Clinical Pharmacology and Therapeutics*, Mar; 89(3):408-15, 2011. **Recommended by F1000.**
8. Cavallari LH, **Perera MA**, Mia Wadelius, MD, Ph.D., ³ Panos Deloukas, Ph.D.⁴ Gelson Taube, Pharm.D.,¹ Shitalben R. Patel, M.S.,¹ Keston Aquino-Michaels, B.A.,² Marlos A.G. Viana, Ph.D.,^{1,5} Nancy L. Shapiro, Pharm.D.,¹ Edith A. Nutescu, Pharm.D. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. *Pharmacogenetics and Genomics.* Feb;22(2):152-8, 2012
9. Lindley K, Limdi N, Cavallari LH, **Perera M**, Lenzini P, Johnson J, Wu A, Ridker P, Patel S, King C, Shah S, Eby C, Beasley TM, Gage BF. Warfarin Dosing in Patients with CYP2C9*5 Variant Alleles. Submitted, *Blood*

10. Gamazon ER, Skol A, **Perera MA**. The Limits of Genome-wide Methods for Pharmacogenomic Testing. *Pharmacogenetics and Genomics*. Apr; 24(4):261-272, 2012
11. Bress A, Patel SR, **Perera MA**, Kittles RA, Campbell RT, Cavallari LH. The effect of NAD(P)H dehydrogenase, quinone 1 (NQO1) genotype on warfarin dose requirements in Hispanic and African Americans. *Clinical Pharmacology and Therapeutics*. 13 (16):1925-1935, 2012
12. Cavallari LH, Vaynshteyn D, Freeman KM, Wang D, **Perera MA**, Takahashi H, Drozda K, Patel SR, Jeong H. CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. *Pharmacogenet Genomics*. Apr;23(4):228-31, 2013
13. Shahin HA, Cavallari LH, **Perera MA**, Khalifa SI, Misher A, Langae T, Patel SR, Perry K, Meltzer DO, McLeod HL, and Johnson JA. *VKORC1* Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. *Thrombosis and Haemostasis Journal*. Jun 4;109(6):1045-50, 2013
14. **Perera MA**, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Pluzhnikov A, Wang J, Liu N, Wagner MJ, Wu A, Roden DM, Crawford DC, Burmester JK, Evertson J, Tector M, Mushiroda T, Kubo M, Altman RB, Klein TE, Rieder MJ, Nakamura Y, Cox NJ, Johnson JA, for the International Warfarin Pharmacogenetics Consortium. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study *Lancet*. Aug 31;382(9894):790-6. 2013 **Recommended by F1000**.
15. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AF, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae D, Cavallari LH, **Perera MA**. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. *Pharmacogenomics J*. Jun;14(3):223-8, 2014
16. Daneshjou R, Tantonetti N, Karczewski KJ, Sagreya H, Bourgeois S, Drazda K, Burmester JK, Tsunoda T, Nakamura Y, Kubo M, Tector M, Limdi NA, Cavallari LH, **Perera MA**, Johnson JA, Klein TE, Altman RB. Pathway Analysis of Genome-Wide Data Improves Warfarin Dose Prediction. *BMC Genomics*, 2013;14 Suppl 3:S11.
17. Madian AG, Panigrahi A, **Perera MA**, Pinto N. Inability to Achieve a Therapeutic Dose of Tacrolimus in a pediatric Stem Cell Transplant Patient due to Generic Substitution. *BMC Pharmacology and Toxicology*, 2014 Dec 3;15:69.
18. Hernandez W, Aquino-Michaels K, Patel S, Jeong H, Takahashi H, Cavallari LH, **Perera MA**. Novel SNPs with in *CYP2C* locus are associated with changes in warfarin clearance in African Americans. *Translational Research*, 2014 Nov 22. pii: S1931-5244(14)00422-8. **Trainee Spotlight Publication**
19. Daneshjou R, Gamazon ER, Burkley B, Cavallari LH, Johnson JA, Klein TE, Limdi N, Hillenmeyer S, Percha B, Karczewski KJ, Langae T, Patel SR, Bustamante CD, Altman RB, **Perera MA**. Genetic Variant in Folate Homeostasis Associated with Warfarin Dose in African Americans. *Blood*, 2014 Oct 2; 124(14):2298-305. **Commentary in Blood 124 (14)**.
20. Nagai R, Ohara M, **Cavallari LH**, Drozda K, Patel SR, Nutescu EA, **Perera MA**, Hernandez W, Kaneko N, Hibiya M, Takahashi H. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. *Pharmacogenomics*. 2015 Mar;16(3):217-25.
21. Hernandez W, Gamazon ER, Smithberger E, O'Brien T, Harrelson A, Tuck M, Barbour A, Kittles RA, Cavallari LH, **Perera MA**. Population specific genomics identifies predictor of Venous Thromboembolism in African Americans. *Blood* Apr. 14; 127(15): 1923-1929. **Press Release by American Society of Hematology, Commentary in Blood 127 (15)**.
22. Daneshjou R, Cavallari LH, Weeke PE, Karczewski KJ, Drozda K, **Perera MA**, Johnson J, Klein TE, Bustamante CD, Roden D, Shaffer C, Denny JC, Zehnder JL, Altman RB. Population-specific single nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. Accepted, *Molecular Genetics & Genomic Medicine*
23. Kubo K, Ohara M, Tachikawa M, Cavallari LH, Lee MTM, Scordo MG, Nutescu E, **Perera MA**, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen YT, Yakahashi H. Population Differences in the Pharmacokinetics of S-warfarin Among African Americans, Asians and Caucasians: Implications for Pharmacogenetic Dosing Algorithms. Accepted, *Pharmacogenomics J*.
24. Hernandez W, Gamazon ER, Aquino-Michaels K, Smithberger E, Patel S, O'Brien TJ, Harralson AF, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Konkashbaev A, Cavallari LH, **Perera MA**. Integrative analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. Resubmitted, *Thrombosis and Haemostasis*.

25. Chang S-W, McDonough C, Gong Y, Johnson T, Tsunoda T, Gamazon ER, **Perera MA**, Takahashi T, Tanaka T, Kubo M, Pepine C, Johnson J, Cooper-DeHoff R. Genome-wide association study identifies pharmacogenomics loci linked with specific antihypertensive drug treatment and new onset Diabetes. Under review, *Pharmacogenomics J*.
26. Gamazon ER, Hernandez W, Patel S, Cavallari LH, **Perera MA**. Tissue specific eQTLs identify novel genetic variant associated with warfarin dose requirement in African Americans. *In preparation*
27. De T, Hernandez W, Nwanze N, Smithberger E, O'Brien TJ, Tuck M, Duarte J, Bourgeois S, **Perera MA**. Novel genomics predictor to bleeding risk in warfarin treated African Americans. Submitted, *Science translational Medicine*.

PEER – REVIEWED INVITED REVIEWS/EDITORIALS

28. **Perera MA**, Innocenti F, Das S, Ratain MJ. Are we there yet? UGT1A1 and Pharmacogenetic testing. Invited review, *Pharmacotherapy* 28(6): 755-768, 2008. PMID: 18503403 [PMCID -in process]
29. **Perera MA**. The Missing Linkage: What pharmacogenetic associations are left to find in *CYP3A*? Invited Review. *Expert Opinion on Drug Metabolism*. Jan;6(1):17-28 (2010) PMID: 19968573 [PMCID - PMC2754748]
30. Cavallari LH, Shin J., **Perera MA**. The Role of Pharmacogenomics in the Management of Traditional and Novel Anticoagulants. *Pharmacotherapy* 2011;31(12):1192–1207
31. Cavallari LH, **Perera MA**. The future of warfarin pharmacogenetics in underrepresented minority groups. *Future Cardiology*, 2012 Jul;8(4):563-76.
32. Gamazon ER, **Perera MA**. Genome –wide approaches in pharmacogenomics: heritability estimation and pharmaco-ethnicity as primary challenges. *Pharmacogenomics* 2012; 13(10): 1101- 1104.
33. **Perera MA**, Cavallari LH, Johnson JA. Warfarin Pharmacogenetics: An illustration of why studies in minority populations are important. *Clinical Pharmacology and Therapeutics*. 2014 Mar;95(3):242-4
34. Cavallari LH, **Perera MA**, Kittle R. Warfarin Pharmacogenetics in Minority Populations. *New England Journal of Medicine*. 2014; 370:1761-1766

INVITED PRESENTATIONS

- | | |
|------|---|
| 2006 | Genetic Variation at the <i>CYP3A</i> Locus: Implications in Drug Metabolism. Research Seminar , University of Illinois, Chicago. |
| 2009 | Lost in Translation: Stories in Clinical Pharmacogenetics. Research Seminar , George Washington University, Washington D.C. |
| 2012 | Uncovering Novel Variation: African Americans in Pharmacogenomic Studies. Research Seminar , University of North Carolina, Chapel Hill. |
| 2012 | What's new in Warfarin Pharmacogenomics: Bringing African Americans to the Forefront. Research Seminar , University of Chicago, Cardiology Grand Rounds |
| 2013 | Using Bioinformatic Analysis to inform Warfarin Pharmacogenomics. Scientific Seminar , University of Florida, College of Pharmacy, Gainesville, FL. |
| 2014 | The integration of “omics” into genome-wide analysis: prediction of drug dose in a minority population. Invited Speaker , 7th Noordwijkerhout Symposium on Pharmacokinetics, Pharmacodynamics and Systems Pharmacology |
| 2014 | Using Bioinformatic Analysis to inform Pharmacogenomics: Bringing African Americans in Personalized Medicine. Research Seminar , University of Illinois |
| 2015 | Using Bioinformatic Analysis to inform Pharmacogenomics in African Americans. Vanderbilt University, Research Seminar |
| 2015 | Warfarin Pharmacogenomics in Minority populations. Invited Session Speaker , Personalized Medicine Conference. Tucson, AZ |
| 2015 | African American Pharmacogenomics, Invited Session Speaker , PGRN-RIKEN Center for Integrative Medical Sciences (IMS) Strategic Alliance Meeting, Yokohama, Japan |

- 2016 African American Pharmacogenomics: Challenge Accepted. **Leon Goldberg Award Lecture**, American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, San Diego FL
- 2016 Novel genetic variants improve bleeding risk prediction in warfarin treated African Americans. **Scientific Session Speaker**, Pharmacogenomics & Precision Medicine Conference, Cape Town, South Africa

ABSTRACTS SELECTED FOR ORAL PRESENTATION

1. **Perera MA**, and Reiner A. "The Cellular Location of DARPP-32, which Implicates the Location of D1 Receptors in the Striatum of Pigeons." Tennessee Academy of Science, Memphis TN, May 1997.
2. **Perera MA**, Limdi NA, Cavallari LH, Gamazon ER, Konkashbaev A, Pluzhnikov A, Wang J, Liu N, Wagner MJ, Wu A, Roden DM, Crawford DC, Burmester JK, Evertson J, Tector M, Mushiroda T, Kubo M, Altman RB, Klein TE, Rieder MJ, Nakamura Y, Cox NJ, Johnson JA, for the International Warfarin Pharmacogenetics Consortium. Novel SNPs Associated with Warfarin Dose in a Large Multicenter Cohort of African Americans: Genome Wide Association Study and Replication Results. American Heart Association (AHA) Scientific Sessions, Orlando FL 2011
3. Bress A, Patel SR, **Perera MA**, Kittles RA, Campbell RT, Cavallari LH. The effect of NAD(P)H dehydrogenase, quinone 1 (NQO1) genotype on warfarin dose requirements in Hispanic and African Americans. American College of Clinical Pharmacy Annual meeting (ACCP), Hollywood, FL 2012
4. **Perera MA**, Daneshjou R, Gamazon ER, Hillenmeyer S, Karczewski K, Klein TE, Langae T, Drozda K, Patel S, Johnson JA, Cavallari LH, Altman RB. Folylpolyglutamate synthetase (*FPGS*) and warfarin: discovery of genes outside of *CYP2C9* and *VKORC1* through exome analysis. Pharmacogenomics Research Network (PGRN) Meeting, Hot Topics, Chicago, IL 2013.
5. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AF, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae DA, Cavallari LH, **Perera MA**. Identification of novel genetic polymorphisms associated with warfarin dose response in African Americans through the use of liver eQTLs. Precision Medicine: Personal Genomes & Pharmacogenomics Meeting, Cold Spring Harbor Laboratories, NY November 2013.
6. Smithberger E, Shen L, Arrieta R, Kwon J, Hanauer S, **Perera MA**. A Novel SNP Predicts Response to Anti-TNF Agents in Inflammatory Bowel Disease. Precision Medicine: Personal Genomes & Pharmacogenomics Meeting, Cold Spring Harbor Laboratories, NY November 2013.
7. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AF, Kittles RK, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae D, Cavallari LH, **Perera MA**. *VKORC1* and *CALU* eQTLs and susceptibility to venous thromboembolism among African Americans. American Society of Clinical Pharmacology and Therapeutics (ASCPT), Atlanta GA April 2014
8. Daneshjou R, Cavallari LH, Karczewski KJ, Drozda K, **Perera MA**, Johnson JA, Klein TE, Weeke PE, Roden D, Altman RB. Single nucleotide polymorphism confers 4-fold risk of venous thromboembolism in African Americans. Pharmacogenomics Research Network (PGRN) Meeting, Hot Topics, Rochester MN, 2014.

BOOK CHAPTERS/INVITED PAPERS

Perera MA, Innocenti F. Pharmacogenetics and Pharmacogenomics: Impact on Drug Discovery and Clinical Care. In *Molecular Diagnostics, 2nd Edition*, Edited by GP. Patrinos, W Ansorge. Amsterdam; Boston: Elsevier Academic Press (2008)

Perera MA. Warfarin: a case for pharmacogenomic testing. *Clinical laboratory Testing*, November (2012)

CURRENT FUNDING

Source: NIH, National Institute of Minority Health and Health Disparities, 1R01MD009217-01
 Title: Health disparity in pharmacogenomics: African American SNPs and drug metabolism
 Time Period: July 2014 – June 2019
 Amount: \$1,250,000 (direct), \$1,984,046 (total)
 Role: Principal Investigator (40% effort)

Source: Patient Centered Outcomes Research Institute
Title: Chicago Area Patient Centered Outcomes Research Network (CAPriCORN)
Time Period: March 2014 – Aug 2015
Amount: \$482,724 (direct), \$675,812 (total)
Role: Co-investigator (2.5% effort), PI: David Meltzer

Source: NIH, National Heart, Lung and Blood Institute, 1 F32 HL123311-01A1
Title: Discovery of genomic copy number variants and expression quantitative trait loci that affect warfarin dose response in African American.
Time Period: April 2015 – March 2017
Amount: \$165,000 (total)
Role: Primary Mentor

PENDING FUNDING

Source: NIH, National Institute of Minority Health and Health Disparities, 1U54MD010723-01
Title: African American Cardiovascular pharmacogenetic CONsorTium (ACCOuNT): discovery and translation
Time Period: July 2016 – June 2021
Amount: \$7,429,807 (direct), \$9,534,933 (total)
Role: Co-Principal Investigator, Contact (25% effort)
Funding Anticipated

COMPLETED FUNDING

Source: NIH, Agency for Healthcare Research and Quality, 1U18HS016967-01
Title: Hospital Medicine and Economics Center for Education and Research on Therapeutics
Time Period: Sept 2007 – Aug. 2010
Role: Co-Investigator (10% effort), PI: David Meltzer

Source: Digestive Disease Research Center Core Pilot and Feasibility Grant, P30 DK42086
Title: Prediction of Response to Anti-TNF alpha agents in Inflammatory Bowel Disease using a Tagging SNP Approach
Time Period: Dec 2008 – Nov 2009
Amount: \$20,000, (12/1/08-11/30/09)
Role: Principle Investigator.

Source: American Heart Association, Midwest Affiliate Clinical Research Program, 10CRP3740026
Title: Clinical Studies of Novel Genetic Variant on Warfarin Dose in African Americans.
Time Period: July 2010 – June 2012
Amount: \$100,000 (direct) \$110,000 (total)
Role: Principal Investigator

Source: NIH, National Heart Lung and Blood Institute, 1 K23 HL089808-01A2,
Title: The implementation of a pharmacogenomics-based algorithm for warfarin dosing
Time Period: July 2009 – June 2014
Amount: \$550,000 (direct), \$594,000 (total)
Role: Principal Investigator

Source: NIH, National Heart Lung and Blood Institute, 1 R21 HL106097-01A1,
Title: Comprehensive studies of novel SNPs affecting warfarin dose in African Americans.
Time Period: August 2011 – July 2014
Amount: \$275,000 (direct), \$437,017 (total)
Role: Principal Investigator

VOLUNTEER WORK

Saltillo Mission, Saltillo Mexico, working with the poor in Mexico, Summer 1997

Champagnate Work Camp, rebuilding houses in rural Mississippi, Summer 1998
Muscular Dystrophy Summer Camp, camp counselor, Summer 2002
Memphis City schools, poison prevention instructor, Summer 2003
Hillel volunteer group, urban renewal projects in and around the city of Columbus,
Chicago Cares Volunteer Organization, urban renewal around the city of Chicago
Feed the Starving Children, assembly of food supplies for famine-stuck area of the globe, 2014